Karo Bio forced to abandon Phase III-stage eprotirome
This article was originally published in Scrip
Karo Bio's future looks uncertain following news that it is dropping its Phase III-stage drug candidate eprotirome after a preclinical study demonstrated "unwanted effects following long-term exposure". As a result, the planned spin-off of the company's preclinical operations into a separate entity will not proceed.
You may also be interested in...
Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.
Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.